Professor Richard Haynes
Research groups
Richard Haynes
DM, MRCP
Professor of Renal Medicine and Clinical Trials
- MSc in Global Health Science module 8 lead: Clinical Trials and Meta-Analysis
Richard Haynes did his pre-clinical medical studies in Cambridge before moving to Oxford for his clinical studies and qualified in 2000. He came to CTSU for a period of “out of programme” research in 2006 to work on the HPS2-THRIVE trial with Prof Jane Armitage. He completed his training in renal medicine in 2011 and was appointed as an honorary consultant at the Oxford Kidney Unit.
Recent publications
-
Effects of Empagliflozin on Fluid Overload, Weight and Blood Pressure in Chronic Kidney Disease
Journal article
Mayne K. et al, (2023), Journal of the American Society of Nephrology
-
Methylprednisolone, intravenous immunoglobulin, tocilizimab or anakinra for children with Paediatric Inflammatory Multisystem Syndrome temporally associated with SARS CoV-2 (PIMS-TS, MIS-C) – report from a randomised, controlled, open-label, platform trial
Journal article
LANDRAY M. et al, (2023), Lancet Child and Adolescent Health
-
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Journal article
PETO L. et al, (2023), Nature Communications
-
Effects of empagliflozin on progression of chronic kidney disease: a pre-specified secondary analysis from the EMPA-KIDNEY trial
Journal article
HAYNES R. et al, (2023), Lancet Diabetes and Endocrinology
-
Impact of Primary Kidney Disease on the Effects of Empagliflozin in Patients with Chronic Kidney Disease: Secondary Analyses of the EMPA-KIDNEY trial
Journal article
Judge P. et al, (2023), Lancet Diabetes and Endocrinology